Moving to the next stage in medical affairs: an analysis in melanoma immunotherapy
With an ever-growing array of new scientific data, medical affairs is evolving into its 2.0 iteration. Now, the skills of medical affairs is being combined with deep, accurate insights to uncover new learnings and capabilities for innovative drugs.
This is particularly true for cardiology and oncology which, whilst experiencing a new age of therapeutics, is in need of informed treatment selection for patients more than ever.
At the same time, communicating the safety and efficacy of these new therapies is no longer enough as medicine moves into an era of value-based decision making. Prescribers are in need of the complete picture when it comes to treating life-threatening conditions, whilst physicians need to understand a medication’s underlying science, what key opinion leaders think about it and what its alternatives are to achieve the best clinical outcomes for their patients.
But with this shift toward value-based care, a well-informed, effective medical affairs team can play a pivotal role in guiding discussions around new therapeutic costs versus clinical outcomes and quality of life.
Of course, these discussions are not limited to a doctor or a payer’s office, but instead will occur throughout the healthcare ecosystem, at conferences and in publications. Being able to identify these discussions and draw insights from them helps medical affairs understand where their data needs to be published and how it should be presented to best influence medical decision making.
To give a sense of how these data can be used we present an infographic snapshot, offering top-line on applications using real data (and anonymised identities) focused on Melanoma.
For more insight on the Future of Medical Affairs – click here